Navigation Links
Avandia Lawsuit Settlement News: 'No News is Bad News,' Says Plaintiffs
Date:4/5/2011

NEW YORK, April 5, 2011 /PRNewswire/ -- The latest news on the much publicized Avandia Settlement's is: there is no news.  After a Bloomberg report made public last summer that many of the Avandia suits were coming to a settlement range of approximately $86,000.00 per suit, no new news has come into the market.  This has left many suffering Avandia plaintiffs with more confusion -and concern- when they will actually get their settlement money.

This has led to many Avandia Plaintiffs to seek lawsuit funding in order to receive some cash to pay bills today, prior to getting their actual settlements.  Once industry that tracks the Avandia litigation is the "legal funding industry," where in March one funding company, lawsuitssettlementfunding.com (Legal-Bay LLC), announced a substantial rise in Avandia lawsuit cash advances.  

Dave Kole, CEO of Lawsuitssettlementfunding.com, spoke about the recent developments, "most of our clients tell us the same thing, they are frustrated with the process.  They are confused because there has been no news in the marketplace about how much they will receive, or worse, when they will actually receive their money.  Many of them were notified that they would have answers by the end of the first quarter, but now that we are in April, they simply can't wait any longer.  I only expect more and more Avandia Plaintiffs to seek lawsuit funding each day this drags on."  

Industry experts believe that the Avandia litigation is getting more complex based on the few articles released of late.  

In January GlaxoSmithKline agreed to take a total of a $3.4bil charge on the expected Avandia settlement.  This is an increase from the $2.4bil charge announced last summer.  The increase raises more questions as to the magnitude of the total settlement; and if Avandia will surpass Vioxx as the largest Pharmaceutical settlement in U.S. History.

Also, in February the Louisiana AG Office sued GlaxoSmithKline for civil fraud involving Avandia.  The increase in more litigation involving Avandia –and the subsequent delays- is now only hurting the people most affected by the drug.  And that is the Avandia long suffering plaintiffs and their families waiting for their settlement money.

Contact and Source:
CNJ Enterprises LLC
Chris Janish, CEO
862-485-7655
Email:  cnjenterprisesllc@gmail.com


'/>"/>
SOURCE CNJ Enterprises LLC
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. DePuy Hip Recall & Avandia Focus of Nov. 3 Conference, HB Announces
2. GSK Regulatory Update on Avandia Following EMA and FDA Reviews
3. American Heart Association Comment: Advisory Committee Recommends that U.S. Food and Drug Administration Keep Rosiglitazone (Avandia) on the Market, Continue Clinical Trial of Safety and Efficacy
4. GlaxoSmithKline Statement in Response to FDA Advisory Committees Vote on Safety of Avandia® (rosiglitazone)
5. GlaxoSmithKline Responds to US Senate Committee on Finance Report on Avandia
6. Large, Long-Term Study Shows Avandia Has No Increased Overall Cardiovascular Risk Compared to Other Commonly Used Diabetes Medicines
7. GSK Believes There Is No Liver Safety Issue With AVANDIA; Responds to Public Citizen Petition
8. FDA Updates Label for AVANDIA(R) to Include Clinical Findings Demonstrating Sustained Glycemic Control for Up to Five Years
9. Two Large, Independent Outcomes Trials Offer New Important Safety Information on Cardiovascular Effects of AVANDIA(R)
10. MultiVu Video Feed: Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA
11. Large, Long-Term Veterans Affairs Diabetes Trial (VADT) Reveals Important Cardiovascular Safety News on AVANDIA(R)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/23/2017)... , February 23, 2017 ... market: the Berlin office was ... Magdalena Kritikos . The portfolio includes Entocort ® ... for the treatment of ulcerative colitis, and VistaPrep ® ... solutions, the Swiss specialty pharmaceutical company focused on the ...
(Date:2/23/2017)... 2017 MabVax Therapeutics Holdings, Inc ... company, announces that it has received notice from ... the initiation a Phase I clinical trial with ... MVT-1075 ( 177 Lu-CHX-A?-DTPA-HuMab5B1) is the Company,s novel ... initiate the phase I clinical trial in patients ...
(Date:2/23/2017)... 23, 2017 Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ... oncology and dermatology biopharmaceutical company, today announced that it ... Rodrigues as special advisers to the Company,s Board ... the board on financial and corporate strategy. ... commitment of up to $2.5 million from Eric ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... The National Academy of Certified ... the April 2017 testing period. NACCM, a nonprofit organization, has provided the premier ... exam is periodically re-calibrated to ensure that newly certified professionals are prepared to ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... understand each Medicare Advantage member’s risk, identify any gaps-in-coding, as well as ... helps transform the HCC Risk Adjustment process from a typical fragmented process ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its steady ... Steven H. Rauchman, practicing at North Valley Eye Medical Group in Mission Hills ... liability and other personal injury cases. These injuries have a major impact on ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... Using the ... leads utilizing a simple online checklist. Over a period of just 24 months, thousands ... assistance of an online checklist called T.A.D. , “The internet is not getting quieter. ...
(Date:2/22/2017)... ... February 22, 2017 , ... The Centers for ... help small practices in Delaware, New Jersey, Pennsylvania and West Virginia prepare for ... and CHIP Reauthorization Act of 2015 (MACRA). , This technical assistance, authorized ...
Breaking Medicine News(10 mins):